
Ready to test 'off-the-shelf' cell therapy
Norwegian biotech Zelluna is entering the clinic for the first time.

Norwegian biotech Zelluna is entering the clinic for the first time.

Two new faces are now a part of the Oslo Cancer Cluster Incubator team.

A new wave of cell therapies is opening possibilities far beyond today’s cancer treatments — and Norway is positioning itself at the centre of the sphere.

«Det var kjempespennende å være her på Sykehusapoteket i dag», sier en entusiastisk Michael B. Lukac. Han og medelev Suhad Khalouf går tredjeåret på apotekteknikk på Ullern videregående skole. Denne dagen har de hatt utplassering hos Sykehusapoteket på Radiumhospitalet og læringskurven har vært bratt.

Can radiopharmaceuticals against cancer become Norway’s Novo Nordisk?

Politicians agree that Norway needs more clinical studies in cancer but are at odds as to how to reach the goals.
Get monthly news updates and invitations to events from our oncology cluster.

Children affected by cancer stepped into real research labs this weekend, gaining hands-on experience with the science behind their treatment through the “Researcher for a Day” programme.

A new arena to accelerate the development of cancer care has been launched in Sweden, building momentum for the European Cancer Mission.

Thor Medical has finished building its AlphaOne facility and begun commissioning, staying on track to start production in the third quarter.

11 elever fra både andre og tredje klasse på Ullern videregående skole fikk være en hel dag hos det franske legemiddelselskapet Sanofis kontorer i Norge på Lysaker. Ungdommene fikk noen aha-opplevelser om hva det vil si å jobbe i et legemiddelselskap, hva slags regler det finnes på feltet og framtidige jobbmuligheter.

An innovative cancer treatment from Norway will be tested for the first time on patients with glioblastoma in the US.

A new collaboration aims to bridge the gap between regulatory approval and the real-world information that clinicians and health authorities need to make informed treatment decisions.

